PUBLISHER: IMARC | PRODUCT CODE: 1661158
PUBLISHER: IMARC | PRODUCT CODE: 1661158
The global isothermal nucleic acid amplification technology market size was valued at USD 3.4 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 8.2 Billion by 2033, exhibiting a CAGR of 10.3% during 2025-2033. North America currently dominates the market, holding a market share of over 43.4% in 2024. The rising demand for fast and accurate diagnostics, increasing prevalence of infectious diseases, rapid advancements in portable testing devices, and expanding applications across healthcare, food safety, and environmental monitoring, with strong support from government initiatives are major factors boosting the isothermal nucleic acid amplification technology market share.
The isothermal nucleic acid amplification technology (INAAT) is used in molecular biology and recombinant DNA technologies for detecting and identifying nucleic acids. It is commonly used to amplify nucleic acids at a constant temperature, thereby eliminating the need for thermocycler equipment. It is majorly utilized for RNA, DNA, cells, proteins, small molecules, and ions to ensure the rapid, sensitive and accurate diagnosis of genetic, inherited, and infectious diseases. It generates amplicons that are employed in producing versatile nucleic acid nanomaterials. Besides this, it assists in detecting various infectious diseases, such as (HIV), tuberculosis, influenza, hepatitis A and B, chlamydia, and gonorrhea (CT/NG). As a result, INAAT is gaining immense traction across the globe.
The ongoing development in INAAT for detecting coronavirus disease (COVID-19) represents one of the key factors positively influencing the market. In line with this, the increasing geriatric population globally and the rising prevalence of cancer and other chronic medical disorders, along with the escalating demand for efficient diagnosis and treatment alternatives, are contributing to the market growth. Apart from this, the adoption of loop-mediated isothermal amplification (LAMP) tests to amplify DNA and RNA and the identification of genetically modified organisms (GMOs) is catalyzing the demand for INAAT. Furthermore, the development of strand displacement amplification (SDA), single primer isothermal amplification (SPIA), and recombinase polymerase amplification (RPA) are acting as another growth-inducing factor. Moreover, increasing investments in research and development (R&D) activities by leading market players are projected to drive the market.
Reagents hold the majority of the global isothermal nucleic acid amplification technology market share due to their increasing use in therapeutics.
TMA accounts for the majority of the total market share as it allows a clinical laboratory to perform nucleic acid test (NAT) assays for blood screening with fewer steps and less processing time.
Infectious disease diagnosis currently dominates the market due to the rising prevalence of infectious diseases across the globe.
Hospitals presently dominate the market due to the increasing number of hospitals and significant development in the healthcare industry.
North America exhibits a clear dominance in the market due to the shifting consumer preference for INAAT testing over traditional diagnostic procedures.
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Some of these players are Abbott Laboratories, bioMerieux SA, Becton, Dickinson and Company, Eiken Chemical Co. Ltd., Hologic Inc., Meridian Bioscience Inc., OptiGene Limited, Thermo Fisher Scientific Inc., Tecan Trading AG, and Ustar Biotechnologies Ltd.